pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Life Biosciences Inc.

updated 5mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 1: 1
1Phase 1
Phase 1
ER-100
Non-Arteritic Anterior Ischemic Optic Neuropathy

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase1Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)recruitingn=18
🐶 Hiring Signal
No open roles indexed yet — view Life Biosciences Inc. jobs →

News

  • STAT+: How the No Surprises Act’s nonprofit arbitrators are operating like ‘mini gods’ and getting rich doing it
    A STAT investigation found that several nonprofits are raking in massive sums by acting as arbitrators in a program that helps protect patients from surprise medical bills.
    stat · 26d ago
  • After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward
    A schoolteacher diagnosed with melanoma provides an inside look at what it was like to be treated with a cancer vaccine developed by Merck and Moderna.
    stat · 1mo ago
  • Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’
    The CEO of Compass Pathways said the company, whose psychedelic therapy is set for regulatory review this year, is prepared to “go slow before we go fast.”
    stat · 1mo ago
  • STAT+: FDA adcomm members’ ties to industry under scrutiny
    New research found that nearly 40% of FDA advisory meetings held over a recent 20-year period included either a patient or consumer rep with active ties to an advocacy group…
    stat · 1mo ago
  • STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug
    Patient advocates and some experts are expressing growing alarm over the perceived risks of a rare disease drug sold by Neurocrine Biosciences.
    stat · 1mo ago
  • STAT+: Hospitals sue – again – to halt Trump administration’s 340B rebate pilot
    The AHA is once again suing the Trump administration over its plan to revamp a federal drug discount program into one that provides after-the-fact rebates instead of upfront discounts.
    stat · 1mo ago
  • STAT+: Medicare Advantage star ratings trigger new bonuses, and uncertainty
    The federal government has released new quality ratings for Medicare Advantage insurers for 2027, with Humana emerging as the biggest winner.
    stat · 1mo ago
  • STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug
    Life Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events.
    stat · 1mo ago
  • City Therapeutics targets $158M IPO; Iambic seeks $135M Nasdaq debut
    Plus news about Alchemist Capital, Newron Pharmaceuticals, Life Biosciences, Onyx Bio and Tecentriq. City Therapeutics charts $158M IPO: The RNAi startup from former Alnylam executives is looking t…
    endpoints · 1mo ago
view all news mentions →
identifiers
source
globaldata
top tags
Ophthalmology1
mentioned in
9news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?